ImmunoGen Inc.

488 articles with ImmunoGen Inc.

• ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

  11/6/2020

  Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin ® in Platinum-Sensitive Ovarian Cancer Presented at ESMO FDA Breakthrough Therapy Designation Received for IMGN632 in Relapsed or Refractory BPDCN

• ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

  11/4/2020

  ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference.

• ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2020

  11/2/2020

  ImmunoGen, Inc. announced that on October 30, 2020 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 21,500 shares of its common stock to a new employee under the ImmunoGen, Inc.

• ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

  10/22/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results.

• ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

  10/19/2020

  Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to Receive Up to $265 Million in Potential Development, Regulatory, and Commercial Milestone Payments

• ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility

  10/12/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM") facility pursuant to its Open Market Sale Agreement SM dated as of September 25, 2020 with Jefferies LLC, as sales agent (the “Sale Agreement”), with participation based on interest

• ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

  10/5/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2020

  10/1/2020

  ImmunoGen, Inc. announced that on September 30, 2020 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 8,400 shares of its common stock to a new employee under the ImmunoGen, Inc.

• ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

  9/17/2020

  Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer

• ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference - Sep 02, 2020

  9/2/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2020

  9/1/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on August 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 79,700 shares of its common stock to five new employees under the ImmunoGen, Inc.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2020

  8/3/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on July 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 16,800 shares of its common stock to a new employee under the ImmunoGen, Inc.

• ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results

  7/31/2020

  Encouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO

• ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference

  7/29/2020

  ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference.

• 

  BioSpace Movers & Shakers, July 24

  7/24/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 22, 2020

  7/22/2020

  ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that in connection with the appointment of Susan Altschuller, PhD as ImmunoGen’s Senior Vice President and Chief Financial Officer, the compensation committee of ImmunoGen’s Board of Directors granted to Dr. Altschuller non-qualified stock option awards under the ImmunoGen, Inc.

• ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer

  7/20/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, PhD has been appointed Senior Vice President and Chief Financial Officer.

• ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results

  7/16/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2020 to discuss its second quarter operating results.

• ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting

  6/22/2020

  Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level

• 

  BioSpace Movers & Shakers, June 5

  6/5/2020

  Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.